Hi Cherie,

Those results on PPMS are quite remarkable considering there is virtually nothing out there used to treat that kind of MS. It makes you wonder, though, why PPMS patients were chosen for such a trial and not also RRMS patients who make up about 85% of MS cases.

I would love to see a head to head trial between LDN , the CRABs and Tysabri. Unfortunately, we'll never see such an event because those expensive medications stand a lot to lose.

Harry